MDV Medivation

SAN FRANCISCO, Feb. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that preclinical efficacy data on MDV3100, a novel small molecule the Company is developing to treat hormone-refractory prostate cancer, will be presented later this month at the Prostate Cancer Symposium, a gathering sponsored by the American Society of Clinical Oncology. Charles Sawyers, M.D., chairman of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, will present the data at 11 a.m. EST on Saturday, February 24, during the "Imaging and Novel Therapeutics" session. The symposium will take place at the Gaylord Palms Resort and Convention Center in Orlando, Florida. MDV3100 was rationally designed to treat hormone-refractory prostate cancer by inhibiting the androgen receptor (AR) differently from currently approved AR antagonist drugs, which are ineffective in treating prostate cancers that have become hormone-refractory. Based in part on the encouraging preclinical efficacy data to be presented by Dr. Sawyers, Medivation plans to begin a Phase 1-2a trial of MDV3100 in patients with hormone-refractory prostate cancer in the first half of this year. About Medivation Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com/. This press release contains forward-looking statements, including statements regarding anticipated clinical trial start dates, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2005, and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2006, June 30, 2006, and September 30, 2006, include more information about factors that could affect the Company's financial and operating results. DATASOURCE: Medivation, Inc. CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners, +1-415-946-1064, for Medivation, Inc. Web site: http://www.medivation.com/

Copyright